

# Microorganisms in the Treatment of Cancer


Jiraphat, Nattawut, Boripat, Aukkawut

# Cancer Treatments




## Mechanism types of microbes for cancer treatment

- As a drug carrier
- As a immune stimulant



Source : Christopher B. Fox(2016), Vaccine Adjuvant



Peptide (black stick and surface) in complex with an MHC class I molecule (red surface)

Source : La Gruta, N., Gras, S., Daley, S., Thomas, P. and Rossjohn, J. (2018). Understanding the drivers of MHC restriction of T cell receptors. *Nature Reviews Immunology*, 18(7), pp.467-478.

# Antitumor Activity of a **Streptococcus pyogenes** Preparation (OK-432). I. Sequential Effector Mechanisms Following a Single **OK-432** Injection in F344 Rats Leading to the Rejection of Syngeneic MADB106 Tumor Cells<sup>1,2,3</sup>


Hiroyasu Fukui<sup>4,5</sup> and Craig W. Reynolds<sup>4,6,7</sup>



Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: <http://www.pediatr-neonatol.com>



CASE REPORT

## Complete Resolution of Retroperitoneal Lymphangioma with a Single Trial of **OK-432** in an Infant



Claudio Olivieri<sup>a,\*</sup>, Lorenzo Nanni<sup>a</sup>, Anna Maria De Gaetano<sup>b</sup>,  
Lucia Manganaro<sup>c</sup>, Claudio Pintus<sup>a</sup>

<sup>a</sup> Pediatric Surgery Unit, Policlinico "A. Gemelli", Rome, Italy

<sup>b</sup> Department of Radiology, Policlinico "A. Gemelli", Rome, Italy

<sup>c</sup> Department of Radiology, Policlinico "Umberto I", Rome, Italy

Received Jan 2, 2013; received in revised form May 14, 2013; accepted Jun 5, 2013

Available online 16 October 2013



# New Treatment Options for Lymphangioma in Infants and Children

Chantal M. Giguère, MD, Nancy M. Bauman, MD, Richard J. H. Smith, MD

First Published December 1, 2002 | Research Article

<https://doi.org/10.1177/000348940211101202>

[Article information](#) ▾

Altmetric 3



## Abstract

Lymphangiomas are congenital malformations of the lymphatic system. These lesions occur most often in the head and neck area, and their treatment continues to be a challenge. Fortunately, a number of advances have occurred in the diagnosis and management of lymphatic malformations in the past decade. The purpose of this article is to clarify the embryology, pathogenesis, histopathology, and classification of these lesions, as well as to describe their various forms of clinical presentation. We provide a complete review of the diagnostic measures available and thoroughly discuss new therapeutic interventions proposed to treat lymphangiomas.

## Keywords

[cervicofacial malformation](#), [congenital malformation](#), [cystic hygroma](#), [head and neck tumor](#), [lymphangioma](#), [lymphovenous malformation](#), [OK-432](#)

# OK-432 (Picibanil)


- Immunostimulant, lyophilized mixture of a low-virulence strain (Su) of group A *Streptococcus pyogenes* incubated with penicillin G.



*Streptococcus pyogenes*

Source : Wikipedia

+



Benzylpenicillin  
(penicillin G)

Lyophilisation




Inactive Ingredients

OK-432

# Lymphangiomas

**Fig 1.** Patient with stage I lymphangioma of right side of his neck. Photographs taken **A)** before and **B)** after 1 injection of OK-432 demonstrate complete response to this treatment.





La Gruta, N., Gras, S., Daley, S., Thomas, P. and Rossjohn, J. (2018). Understanding the drivers of MHC restriction of T cell receptors. *Nature Reviews Immunology*, 18(7), pp.467-478.



# Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions

Ouajdi Felfoul, Mahmood Mohammadi, Samira Taherkhani, Dominic de Lanauze, Yong Zhong Xu, Dumitru Loghin, Sherief Essa, Sylwia Jancik, Daniel Houle, Michel Lafleur, Louis Gaboury, Maryam Tabrizian, Neila Kaou, Michael Atkin, Té Vuong, Gerald Batist, Nicole Beauchemin, Danuta Radzioch & Sylvain Martel 


*Nature Nanotechnology* **11**, 941–947 (2016) | [Download Citation](#) 




**Magnetosome** are membranous structures present in magnetotactic bacteria (MTB). They contain iron-rich magnetic particles that are enclosed within a lipid bilayer membrane. (Wikipedia)

*Magnetococcus marinus* MC-1







Source : [microbewiki.kenyon.edu/index.php/Magnetococcus\\_marinus\\_MC-1](http://microbewiki.kenyon.edu/index.php/Magnetococcus_marinus_MC-1)







Liposome with drugs



# References

- Felfoul, O., Mohammadi, M., Taherkhani, S., de Lanauze, D., Zhong Xu, Y., Loghin, D., Essa, S., Jancik, S., Houle, D., Lafleur, M., Gaboury, L., Tabrizian, M., Kaou, N., Atkin, M., Vuong, T., Batist, G., Beauchemin, N., Radzioch, D. and Martel, S. (2016). Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions. *Nature Nanotechnology*, 11(11), pp.941-947.
- Giguère, C., Bauman, N. and Smith, R. (2002). New Treatment Options for Lymphangioma in Infants and Children. *Annals of Otolaryngology, Rhinology & Laryngology*, 111(12), pp.1066-1075.
- La Gruta, N., Gras, S., Daley, S., Thomas, P. and Rossjohn, J. (2018). Understanding the drivers of MHC restriction of T cell receptors. *Nature Reviews Immunology*, 18(7), pp.467-478.